Interview with the CEO: Asterias Biotherapeutics, Inc. (NYSEMKT:AST)

Healthcare >> Analyst Interviews >> August 12, 2016

Steve Cartt joined Asterias Biotherapeutics, Inc. in February 2016 as Chief Executive Officer. Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals, Inc., from February 2012 until August 2014, when the company was acquired by Mallinckrodt plc. Mr. Cartt served as Chief Operating Officer of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc on an interim basis following the merger with Questcor Pharmaceuticals, Inc. from August 2014 until October 2014. Mr. Cartt joined Questcor Pharmaceuticals, Inc. as Executive Vice President, Corporate Development, during March 2005. He was later appointed Chief Business Officer before being appointed Chief Operating Officer. Mr. Cartt was a private consultant from August 2002 until March 2005. From March 2000 through August 2002, Mr. Cartt was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Prior to that, Mr. Cartt held a variety of R&D and commercial positions at ALZA Corporation during the period July 1985 to March 2000. Mr. Cartt holds a B.S. from the University of California at Davis in biochemistry and an MBA from Santa Clara University. Profile

TWST: Could you provide a brief history of Asterias Biotherapeutics and talk about what its technology is and where it stands today?

Mr. Cartt: Asterias has

Join for free to read a longer excerpt or purchase this article

Interview with the CEO: Asterias Biotherapeutics, Inc. (NYSEMKT:AST)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO: Asterias Biotherapeutics, Inc. (NYSEMKT:AST)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS